Taysha Gene Therapies
TSHA
46 hedge funds and large institutions have $358M invested in Taysha Gene Therapies in 2021 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 8 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.89% less ownership
Funds ownership: 47.67% → 46.77% (-0.89%)
10% less funds holding
Funds holding: 51 → 46 (-5)
25% less capital invested
Capital invested by funds: $475M → $358M (-$117M)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$8.65M |
| 2 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
+$4.85M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$1.22M |
| 4 |
BlackRock
New York
|
+$851K |
| 5 |
DC
Davenport & Co
Richmond,
Virginia
|
+$546K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$10.4M |
| 2 |
DM
Deerfield Management
New York
|
-$6.63M |
| 3 |
Sands Capital Management
Arlington,
Virginia
|
-$2.59M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.13M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$949K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CIP
51
Chartwell Investment Partners
Berywn,
Pennsylvania
| – | -$497K | -18,737 | Closed |
|
52
Goldman Sachs
New York
| – | -$392K | -14,763 | Closed |
|
53
Point72 Asset Management
Stamford,
Connecticut
| – | -$355K | -13,366 | Closed |
|
|
CSS
54
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$118K | -4,453 | Closed |
|
TSHA Hedge Fund Activity: Q1 2021 in Review
46 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q1 2021, worth a combined $358M — down 25% from $475M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TSHA and 3 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 17 added.
The largest buyer was Franklin Resources, adding an estimated $8.65M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $10.4M sold.
- 46 institutional investors held Taysha Gene Therapies (TSHA) as of Q1 2021, down from 51 in Q4 2020.
- Funds reported $358M of Taysha Gene Therapies stock for Q1 2021, down 25% quarter-over-quarter.
- 3 funds opened new Taysha Gene Therapies positions in Q1 2021 and 8 closed out, a net change of -5 holders.
- The largest Taysha Gene Therapies buyer in Q1 2021 was Franklin Resources, an estimated $8.65M added.
- The largest Taysha Gene Therapies seller in Q1 2021 was Avidity Partners Management, an estimated $10.4M sold.
Based on aggregated 13F filings for Q1 2021.